Generation of functional CD8+ T Cells by human dendritic cells expressing glypican-3 epitopes

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  O'Beirne, James ^a,b   Farzaneh, Farzin ^a   Harrison, Phillip M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLYPICAN 3; HLA A2 ANTIGEN; LIPOPOLYSACCHARIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESSENGER RNA; EPITOPE; GLYPICAN;

ARTICLE; BINDING AFFINITY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; LYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYNTHESIS; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; METABOLISM; TUMOR CELL LINE;

CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; GLYPICANS; HLA-A2 ANTIGEN; HUMANS; RNA, MESSENGER; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION;

EID: 77952075646     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-48     Document Type: Article

References (45)

1. Human tumor antigens for cancer vaccine development. Wang RF, Rosenberg SA, Immunol Rev 1999 170 85 100 10.1111/j.1600-065X.1999.tb01331.x 10566144 (Pubitemid 29490747)
2. Global cancer statistics, 2002. Parkin DM, Bray F, Ferlay J, Pisani P, CA Cancer J Clin 2005 55 74 108 10.3322/canjclin.55.2.74 15761078 (Pubitemid 40372904)
3. The role of the immune system in the control of hepatocellular carcinoma. O'Beirne JP, Harrison PM, Eur J Gastroenterol Hepatol 2004 16 1257 1260 10.1097/00042737-200412000-00003 15618828 (Pubitemid 39627521)
4. Spontaneous regression of hepatocellular carcinoma. Gaffey MJ, Joyce JP, Carlson GS, Esteban JM, Cancer 1990 65 2779 2783 10.1002/1097-0142(19900615)65: 12<2779::AID-CNCR2820651228>3.0.CO;2-T 2160319 (Pubitemid 20179557)
5. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, Li YW, Tang ZY, J Clin Oncol 2007 25 2586 2593 10.1200/JCO.2006.09.4565 17577038 (Pubitemid 47041232)
6. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T, Lancet 2000 356 802 807 10.1016/S0140-6736(00)02654-4 11022927
7. Adoptive T cell therapy of solid cancers. Knutson KL, Wagner W, Disis ML, Cancer Immunol Immunother 2006 55 96 103 10.1007/s00262-005-0706-1 15891880 (Pubitemid 41783299)
8. Expression pattern of glypican-3 (GPC3) during human embryonic and fetal development. Iglesias BV, Centeno G, Pascuccelli H, Ward F, Peters MG, Filmus J, Puricelli L, de Kier Joffe EB, Histol Histopathol 2008 23 1333 1340 18785116
9. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, Filmus J, Gastroenterology 2003 125 89 97 10.1016/S0016-5085(03)00689-9 12851874 (Pubitemid 36799110)
10. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Shirakawa H, Suzuki H, Shimomura M, Kojima M, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kobayashi N, Kinoshita T, Nakatsura T, Cancer Sci 2009 100 1403 1407 10.1111/j.1349-7006.2009.01206.x 19496787
11. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice. Motomura Y, Ikuta Y, Kuronuma T, Komori H, Ito M, Tsuchihara M, Tsunoda Y, Shirakawa H, Baba H, Nishimura Y, Kinoshita T, Nakatsura T, Int J Oncol 2008 32 985 990 18425324
12. Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice. Nakatsura T, Komori H, Kubo T, Yoshitake Y, Senju S, Katagiri T, Furukawa Y, Ogawa M, Nakamura Y, Nishimura Y, Clin Cancer Res 2004 10 8630 8640 10.1158/1078-0432. CCR-04-1177 15623647 (Pubitemid 40053431)
13. Embryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10. Motomura Y, Senju S, Nakatsura T, Matsuyoshi H, Hirata S, Monji M, Komori H, Fukuma D, Baba H, Nishimura Y, Cancer Res 2006 66 2414 2422 10.1158/0008-5472.CAN-05-2090 16489048
14. Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma. Hiroishi K, Eguchi J, Baba T, Shimazaki T, Ishii S, Hiraide A, Sakaki M, Doi H, Uozumi S, Omori R, Matsumura T, Yanagawa T, Ito T, Imawari M, J Gastroenterol 2010 45 451 458 10.1007/s00535-009-0155-2 19936602
15. SYFPEITHI. http://www.syfpeithi.de/Scripts/MHCServer.dll/ EpitopePrediction.htm
16. HLAmotif. http://bimas.dcrt.nih.gov
17. RankPep. http://immunax.dfci.harvard.edu/Tools
18. Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. Butterfield LH, Koh A, Meng W, Vollmer CM, Ribas A, Dissette V, Lee E, Glaspy JA, McBride WH, Economou JS, Cancer Res 1999 59 3134 3142 10397256 (Pubitemid 29316013)
19. T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein. Butterfield LH, Meng WS, Koh A, Vollmer CM, Ribas A, Dissette VB, Faull K, Glaspy JA, McBride WH, Economou JS, J Immunol 2001 166 5300 5308 11290817 (Pubitemid 32280749)
20. ATP is required for in vitro assembly of MHC class I antigens but not for transfer of peptides across the ER membrane. Levy F, Gabathuler R, Larsson R, Kvist S, Cell 1991 67 265 274 10.1016/0092-8674(91)90178-2 1913823 (Pubitemid 121001442)
21. Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay. Stuber G, Leder GH, Storkus WT, Lotze MT, Modrow S, Szekely L, Wolf H, Klein E, Karre K, Klein G, Eur J Immunol 1994 24 765 768 10.1002/eji.1830240341 8125143 (Pubitemid 24076647)
22. Erythroid cell-specific mRNA stability elements in the alpha 2-globin 3' nontranslated region. Weiss IM, Liebhaber SA, Mol Cell Biol 1995 15 2457 2465 7739530
23. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. Romani N, Reider D, Heuer M, Ebner S, Kampgen E, Eibl B, Niederwieser D, Schuler G, J Immunol Methods 1996 196 137 151 10.1016/0022-1759(96)00078-6 8841452 (Pubitemid 26306735)
24. Glypican-3 is overexpressed in human hepatocellular carcinoma. Sung YK, Hwang SY, Park MK, Farooq M, Han IS, Bae HI, Kim JC, Kim M, Cancer Sci 2003 94 259 262 10.1111/j.1349-7006.2003.tb01430.x 12824919 (Pubitemid 36575892)
25. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y, Hosaka S, Beppu T, Ishiko T, Kamohara H, Ashihara H, Katagiri T, Furukawa Y, Fujiyama S, Ogawa M, Nakamura Y, Nishimura Y, Biochem Biophys Res Commun 2003 306 16 25 10.1016/S0006-291X(03)00908-2 12788060 (Pubitemid 36629398)
26. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Llovet JM, Chen Y, Wurmbach E, Roayaie S, Fiel MI, Schwartz M, Thung SN, Khitrov G, Zhang W, Villanueva A, Battiston C, Mazzaferro V, Bruix J, Waxman S, Friedman SL, Gastroenterology 2006 131 1758 1767 10.1053/j.gastro.2006.09.014 17087938 (Pubitemid 46001394)
27. Distinction of Hepatocellular Carcinoma From Benign Hepatic Mimickers Using Glypican-3 and CD34 Immunohistochemistry. Coston WM, Loera S, Lau SK, Ishizawa S, Jiang Z, Wu CL, Yen Y, Weiss LM, Chu PG, Am J Surg Pathol 2008 32 433 444 10.1097/PAS.0b013e318158142f 18300806 (Pubitemid 351398936)
28. Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy. Anatelli F, Chuang ST, Yang XJ, Wang HL, Am J Clin Pathol 2008 130 219 223 10.1309/WMB5PX57Y4P8QCTY 18628090
29. Glypican-3 expression in benign liver tissue with active hepatitis C: implications for the diagnosis of hepatocellular carcinoma. Abdul-Al HM, Makhlouf HR, Wang G, Goodman ZD, Hum Pathol 2008 39 209 212 10.1016/j.humpath. 2007.06.004 17949778
30. Cell surface proteoglycan expression during maturation of human monocytes-derived dendritic cells and macrophages. Wegrowski Y, Milard AL, Kotlarz G, Toulmonde E, Maquart FX, Bernard J, Clin Exp Immunol 2006 144 485 493 10.1111/j.1365-2249.2006.03059.x 16734618 (Pubitemid 43799932)
31. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Komori H, Nakatsura T, Senju S, Yoshitake Y, Motomura Y, Ikuta Y, Fukuma D, Yokomine K, Harao M, Beppu T, Matsui M, Torigoe T, Sato N, Baba H, Nishimura Y, Clin Cancer Res 2006 12 2689 2697 10.1158/1078-0432.CCR-05-2267 16675560
32. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Schubert U, Anton LC, Gibbs J, Norbury CC, Yewdell JW, Bennink JR, Nature 2000 404 770 774 10.1038/35004754 10783891 (Pubitemid 30212405)
33. Antigen processing by the proteasome. Kloetzel PM, Nat Rev Mol Cell Biol 2001 2 179 187 10.1038/35056572 11265247 (Pubitemid 33675742)
34. Glypican-3 (GPC3)-Derived Tumor Rejection Antigenic Peptides Useful For HLA-A2-Positive Patients And Pharmaceutical Comprising The Same. Nishimura Y, Nakatsura T, Komori H, Patent City: Kumamoto University 2009 AA61K3808FI
35. Identification of noncanonical melanoma-associated T cell epitopes for cancer immunotherapy. Bredenbeck A, Losch FO, Sharav T, Eichler-Mertens M, Filter M, Givehchi A, Sterry W, Wrede P, Walden P, J Immunol 2005 174 6716 6724 15905511 (Pubitemid 40705633)
36. Selection and fine-tuning of the autoimmune T-cell repertoire. Anderton SM, Wraith DC, Nat Rev Immunol 2002 2 487 498 10.1038/nri842 12094223 (Pubitemid 37328740)
37. Immunoproteasome down-modulation enhances the ability of dendritic cells to stimulate antitumor immunity. Dannull J, Lesher DT, Holzknecht R, Qi W, Hanna G, Seigler H, Tyler DS, Pruitt SK, Blood 2007 110 4341 4350 10.1182/blood-2007-04-083188 17855630 (Pubitemid 351377799)
38. Gradual upregulation of OCI-5 expression during occurrence and progression of rat hepatocellular carcinoma. Jiang WJ, Man XB, Tang L, Song HY, Li SJ, Cai GJ, Qiu XH, Hu HP, Hepatobiliary Pancreat Dis Int 2006 5 257 261 16698587 (Pubitemid 43826919)
39. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Capurro MI, Xiang YY, Lobe C, Filmus J, Cancer Res 2005 65 6245 6254 10.1158/0008-5472.CAN-04-4244 16024626 (Pubitemid 40994410)
40. Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Lai JP, Sandhu DS, Yu C, Han T, Moser CD, Jackson KK, Guerrero RB, Aderca I, Isomoto H, Garrity-Park MM, Zou H, Shire AM, Nagorney DM, Sanderson SO, Adjei AA, Lee JS, Thorgeirsson SS, Roberts LR, Hepatology 2008 47 1211 1222 10.1002/hep.22202 18318435 (Pubitemid 351547907)
41. An update on the molecular genetics of hepatocellular carcinoma. Suriawinata A, Xu R, Semin Liver Dis 2004 24 77 88 10.1055/s-2004-860865 15085488 (Pubitemid 40052627)
42. Caught up in a Wnt storm: Wnt signaling in cancer. Giles RH, van Es JH, Clevers H, Biochim Biophys Acta 2003 1653 1 24 12781368 (Pubitemid 36627817)
43. siRNA-mediated beta-catenin knockdown in human hepatoma cells results in decreased growth and survival. Zeng G, Apte U, Cieply B, Singh S, Monga SP, Neoplasia 2007 9 951 959 10.1593/neo.07469 18030363 (Pubitemid 350086440)
44. Involvement of glypican-3 in the recruitment of M2-polarized tumor-associated macrophages in hepatocellular carcinoma. Takai H, Ashihara M, Ishiguro T, Terashima H, Watanabe T, Kato A, Suzuki M, Cancer Biol Ther 2009 8 2329 2338 10.1158/1535-7163.MCT-09-0150 19838081
45. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Van Tendeloo VF, Ponsaerts P, Lardon F, Nijs G, Lenjou M, Van Broeckhoven C, Van Bockstaele DR, Berneman ZN, Blood 2001 98 49 56 10.1182/blood.V98.1.49 11418462